The Effect of SGLT2 Inhibitor Dapagliflozin on BMI in Female Adolescents with Type 1 Diabetes

被引：0
|
作者：
Roman, R. [1 ]
Valdivia, N. [2 ]
Ruiz, S. [3 ]
机构：
[1] Univ Antofagasta, Hosp Reg Antofagasta, Antofagasta, Chile
[2] Univ Antofagasta, Antofagasta, Chile
[3] Hosp Reg Antofagasta, Antofagasta, Chile
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2015年 / 84卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O15
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [21] The effect of SGLT2 inhibitor dapagliflozin on substrate metabolism in humans with prediabetes
    Veelen, A.
    Andriessen, C.
    Op den Kamp, Y.
    Tapia, E. Erazo
    de Ligt, M.
    Mevenkamp, J.
    Jorgensen, J.
    Moonen-Kornips, E.
    Schaart, G.
    Havekes, B.
    Oscarsson, J.
    Schrauwen-Hinderling, V.
    Phielix, E.
    Schrauwen, P.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S6 - S6
  • [22] DAPAGLIFLOZIN, A SELECTIVE SGLT2 INHIBITOR, IMPROVED GLYCEMIC CONTROL OVER 2 WEEKS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
    Kasichayanula, S.
    Griffen, S. C.
    Chalamandaris, A.
    LaCreta, F.
    Boulton, D. W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S19 - S20
  • [23] SGLT2 inhibition with dapagliflozin A novel approach for the management of type 2 diabetes
    Kilov, Gary
    Leow, Stephen
    Thomas, Merlin
    AUSTRALIAN FAMILY PHYSICIAN, 2013, 42 (10) : 706 - 710
  • [24] The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation
    Cho, Yongin
    Shin, Sung-Hee
    Park, Min-Ae
    Suh, Young Ju
    Park, Sojeong
    Jang, Ji-Hun
    Kim, Dae-Young
    Kim, So Hun
    PLOS ONE, 2025, 20 (02):
  • [25] THE SGLT2 INHIBITOR DAPAGLIFLOZIN IMPROVES ERECTILE DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROSPECTIVE STUDY
    Cannarella, Rossella
    Condorelli, Rosita A. Angela
    Leanza, Claudia
    Garofalo, Vincenzo
    Lundy, Scott
    Calogero, Aldo E.
    La Vignera, Sandro
    FERTILITY AND STERILITY, 2023, 120 (04) : E245 - E246
  • [26] Effects of 5 weeks of treatment with dapagliflozin, a SGLT2 inhibitor, on energy metabolism in patients with type 2 diabetes
    Op den Kamp, Y.
    de Ligt, M.
    Dautzenberg, B. D.
    Esterline, R.
    Hoeks, J.
    Schrauwen-Hinderling, V. B.
    Havekes, B.
    Oscarsson, J.
    Phielix, E.
    Schrauwen, P.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S115 - S115
  • [27] Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin
    Jabbour, Serge A.
    Whaley, Jean M.
    Tirmenstein, Mark
    Poucher, Simon M.
    Reilly, Timothy P.
    Boulton, David W.
    Saye, JoAnne
    List, James F.
    Parikh, Shamik
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 62 - 73
  • [28] Dapagliflozin, a selective SGLT2 inhibitor, has a low propensity to cause hypoglycaemia in patients with type 2 diabetes
    Rohwedder, K.
    Hrub, V.
    Salsali, A.
    Ying, L.
    Sugg, J.
    List, J. F.
    Parikh, S.
    DIABETOLOGIA, 2011, 54 : S348 - S349
  • [29] Dapagliflozin, a selective SGLT2 inhibitor, reduces serum levels of uric acid in patients with type 2 diabetes
    Hardy, E.
    Rohwedder, K.
    Hrub, V.
    Salsali, A.
    Ying, L.
    Sugg, J.
    List, J. F.
    Parikh, S.
    DIABETOLOGIA, 2011, 54 : S344 - S345
  • [30] Dapagliflozin. SGLT2 inhibitor, Antidiabetic agent
    Cole, P.
    Vicente, M.
    Castaner, R.
    DRUGS OF THE FUTURE, 2008, 33 (09) : 745 - 751
12345